ARK Invest bought 359,612 Rocket Lab shares for approximately $25.1 million through its ARKK, ARKQ and ARKX exchange-traded funds, while selling 16,422 Alphabet shares for roughly $5.8 million. The transaction brings ARK’s Rocket Lab holdings above 3.2 million shares, worth about $225 million at current prices. Rocket Lab’s long-term expansion strategy centers on Neutron, a next-generation reusable launch system designed for the medium-lift market, with an initial launch targeted for the fourth quarter of 2026. Management has said qualification testing could push the inaugural flight into 2027. ARK also increased its biotechnology exposure through purchases of Scribe Therapeutics, Veracyte and Beam Therapeutics, while reducing positions in Twist Bioscience, 10X Genomics and Everpure. The trades reflect ARK’s continued focus on aerospace, biotechnology and other disruptive-technology themes.